Evidence map›Paper›PMID 35057779›Full record

ArticleBMC complementary medicine and therapies2022

Arrabidaea chica chloroform extract modulates estrogen and androgen receptors on luminal breast cancer cells.

Douglas C Brandão, Paula M A P Lima, Isabella C Martins, Carina S Cordeiro, Antonielle O Cordeiro, Lara Vecchi, Joyce F C Guerra, Priscila C Orsolin, Matheus C Gazolla, Danilo S Costa and 2 more

Open access · goldAbstract read
In one paragraph

Article in BMC complementary medicine and therapies, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 9 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Douglas C BrandãoLaboratory of Genetics and Biotechnology, Institute of Biotechnology, Federal University of Uberlandia, Rua Major Jerônimo, 566, Sala 601, Patos de Minas, MG, 38700-002, Brazil.
Paula M A P LimaLaboratory of Genetics and Biotechnology, Institute of Biotechnology, Federal University of Uberlandia, Rua Major Jerônimo, 566, Sala 601, Patos de Minas, MG, 38700-002, Brazil.
Isabella C MartinsLaboratory of Genetics and Biotechnology, Institute of Biotechnology, Federal University of Uberlandia, Rua Major Jerônimo, 566, Sala 601, Patos de Minas, MG, 38700-002, Brazil.
Carina S CordeiroLaboratory of Genetics and Biotechnology, Institute of Biotechnology, Federal University of Uberlandia, Rua Major Jerônimo, 566, Sala 601, Patos de Minas, MG, 38700-002, Brazil.
Antonielle O CordeiroLaboratory of Genetics and Biotechnology, Institute of Biotechnology, Federal University of Uberlandia, Rua Major Jerônimo, 566, Sala 601, Patos de Minas, MG, 38700-002, Brazil.
Lara VecchiLaboratory of Nanobiotechnology, Institute of Biotechnology, Federal University of Uberlandia, Uberlandia, MG, Brazil.
Joyce F C GuerraInstitute of Biotechnology, Federal University of Uberlandia, Patos de Minas, MG, Brazil.
Priscila C OrsolinLaboratory of Cytogenetic and Mutagenesis, University Center of Patos de Minas, Patos de Minas, MG, Brazil.
Matheus C GazollaFaculty of Pharmacy, Department of Pharmaceutical Sciences, Federal University of Juiz de Fora, Juiz de Fora, MG, Brazil.
Danilo S CostaFaculty of Pharmacy, Department of Pharmaceutical Sciences, Federal University of Juiz de Fora, Juiz de Fora, MG, Brazil.
Ademar A da Silva FilhoFaculty of Pharmacy, Department of Pharmaceutical Sciences, Federal University of Juiz de Fora, Juiz de Fora, MG, Brazil.
Thaise G AraújoLaboratory of Genetics and Biotechnology, Institute of Biotechnology, Federal University of Uberlandia, Rua Major Jerônimo, 566, Sala 601, Patos de Minas, MG, 38700-002, Brazil. tgaraujo@ufu.br.
Universidade Federal de Uberlândia · BRUniversidade Federal de Juiz de Fora · BRCentro Universitário de Patos de Minas · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBreast Cancer (BC) is the most common cancer in women worldwide and, although 70% of patients are responsive to selective Estrogen Receptor (ER) modulators such as Tamoxifen (Tam), patients' survival is comprised by resistance to endocrine therapy. Brazilian flora, especially the Amazon biome, is one of the richest global sources of native species with potentially bioactive compounds. Arrabidaea chica is a plant native to the Amazon that has been used in the treatment of different diseases. However, its action on BC remains unclear.

methodsHerein the biological effects of the chloroform extract of A. chica (CEAC) were evaluated on BC cells and in in vivo model. After confirmation of CEAC antioxidant capacity, cells were treated with CEAC and Tam, alone and with CEAC+Tam. The cell viability was evaluated by MTT and hormone receptor transcripts levels were assessed (ESR1, ESR2 and AR). Finally, anticarcinogenicity of CEAC was recorded in Drosophila melanogaster through Epithelial Tumor Test (ETT).

resultsThe study confirmed the antioxidant activity of CEAC. CEAC was selective for MCF-7, downregulating ESR2 and AR transcripts and upregulating ESR2 expression. The modulatory effects of CEAC on ERs did not differ between cells treated with Tam and with CEAC+Tam. Interestingly, previous treatment with CEAC, followed by treatment with Tam promoted a significant decrease in cell viability. The extract also presented anticarcinogenic effect in in vivo assay.

conclusionThe bioassays on breast tumor cells demonstrated the antiproliferative activity of the extract, which modulated the expression of hormone receptors and sensitized luminal tumor cells to Tam. These results suggest that CEAC could be a complementary treatment for BC.

Indexed as

BignoniaceaePhytotherapyAnimalsAnticarcinogenic AgentsAntioxidantsBiological AssayBreast NeoplasmsCell Line, TumorCell ProliferationCell SurvivalDrosophila melanogasterDrug Resistance, NeoplasmEstrogen Receptor alphaEstrogen Receptor betaFemaleHumansAnticarcinogenic AgentsAntioxidantsESR1 protein, humanESR2 protein, humanEstrogen Receptor alphaEstrogen Receptor betaPlant ExtractsReceptors, AndrogenBreast CancerCarcinogenicityHormone ReceptorsHormonotherapyNatural Products

Identifiers

PMID35057779
PMCPMC8773405
OpenAlexW4205232715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.